Managing Director & CEO Transition
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Dr. Cheri Walker has been appointed as interim CEO, bringing extensive experience in the diagnostics market and a history with Atomo, having served on the Board since the previous year. The Board will initiate a global search for a permanent CEO while Mr. Kelly will assist Dr. Walker during the transition period.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Atomo Diagnostics
- Share Purchase Plan Results
- Response to ASX Aware Letter
- Atomo Completes Capital Raise
- FebriDx FDA CLIA wavier approval unlocks upside for Pascal
- Trading Halt
Later from Atomo Diagnostics
- 2026 Appendix 4E and Annual Report
- Atomo Signs Agreement with Innovation Scientific
- Quarterly Activities/Appendix 4C Cash Flow Report
- Q1 FY27 Results Presentation
Follow Atomo Diagnostics into a list and get an email when it puts out news.
Follow Atomo Diagnostics